.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 8,920,781

« Back to Dashboard

Details for Patent: 8,920,781

Title:Carrier particles for use in dry powder inhalers
Abstract: A powder for use in a dry powder inhaler includes active particles and carrier particles for carrying the active particles. The powder further includes additive material on the surfaces of the carrier particles to promote the release of the active particles from the carrier particles on actuation of the inhaler. The powder is such that the active particles are not liable to be released from the carrier particles before actuation of the inhaler. The inclusion of additive material in the powder has been found to give an increased respirable fraction of the active material.
Inventor(s): Staniforth; John Nicholas (Bath, GB)
Assignee: Vectura Limited (Chippenham, Wiltshire, GB)
Filing Date:Mar 26, 2010
Application Number:12/748,275
Claims:1. A powder for use in a dry powder inhaler, the powder comprising active particles and carrier particles for carrying the active particles, the powder further including particles of additive material attached to the surfaces of the carrier particles, wherein particles of additive material adhere to the high energy sites on the surfaces of the carrier particles and wherein the powder comprises more than one additive material, wherein the additive material includes one or more surface active materials; wherein additive particles are also present as agglomerates and act as carriers of the active particles and are separate from or separable from the surfaces of the carrier particles with active particles attached to surfaces of the agglomerates.

2. A powder according to claim 1 wherein the powder includes not more than 5% by weight of additive material based on the weight of the powder.

3. A powder according to claim 2 wherein the powder includes not more than 2% by weight of additive material based on the weight of the powder.

4. A powder according to 1 wherein the carrier particles are comprised of one or more crystalline sugars.

5. A powder according to claim 4 wherein the carrier particles are particles of lactose.

6. A powder according to claim 1 wherein the additive material consists of physiologically acceptable material.

7. A powder according to claim 1, wherein the additive material is an anti-adherent material.

8. A powder according to claim 1, wherein the additive material is an anti-friction agent.

9. A powder according to claim 1, wherein the additive material includes magnesium stearate.

10. A powder according to claim 1, wherein the additive particles are angular or dendritic in shape.

11. A powder according to claim 1, wherein the additive particles are plate-like particles.

12. A powder according to claim 1, wherein the powder consists of not less than 0.1% by weight of additive particles based on the weight of the carrier particles.

13. A powder according to claim 1, wherein the additive material forms a discontinuous covering on the surfaces of the carrier particles.

14. A powder according to claim 1, wherein the active particles include a .beta.2-agonist.

15. A method of producing particles according to claim 1, the method including the step of mixing carrier particles of a size suitable for use in dry powder inhalers with additive material which becomes attached to the surfaces of the carrier particles.

16. A method according to claim 15 wherein the method further includes the step of treating the carrier particles to dislodge small grains from the surfaces of the carrier particles, without substantially changing the size of the carrier particles during the treatment.

17. A method according to claim 16 wherein the small grains become reattached to the surfaces of the carrier particles.

18. A powder for use in a dry powder inhaler, the powder including additive and carrier particles for carrying the additive particles, the powder further including active particles which adhere to the additive particles on the carrier particles, wherein the additive material is magnesium stearate, wherein the additive material is present in an amount of not more than 1% by weight based on the weight of the powder; wherein additive particles are also present as agglomerates and act as carriers of the active particles and are separate from or separable from the surfaces of the carrier particles with active particles attached to surfaces of the agglomerates.

19. A powder according to claim 1, wherein the more than one additive material comprises magnesium stearate.

20. A powder according to claim 1, wherein the additive particles are non-spherical.

21. A powder according to claim 20, wherein the particles are plate-like, angular or dendritic.

22. A powder according to claim 18, wherein the additive particles are non-spherical.

23. A powder according to claim 22, wherein the particles are plate-like, angular or dendritic.

24. A powder for use in a dry powder inhaler, the powder comprising: active particles; carrier particles for carrying the active particles; and particles of additive material attached to surfaces of the carrier particles; wherein the particles of additive material adhere to high energy sites on the surfaces of the carrier particles and provide a discontinuous covering for the carrier particles, wherein the powder comprises more than one additive material in the form of a powder, and wherein the additive material includes one or more surface active materials; wherein additive particles are also present as agglomerates and act as carriers of the active particles and are separate from or separable from the surfaces of the carrier particles with active particles attached to surfaces of the agglomerates.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc